Epitranscriptomic Therapies Market Report Infographic Image

Published : February 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Epitranscriptomic Therapies Market Report 2026

Name: Epitranscriptomic Therapies Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Therapy Type (Small Molecule Inhibitors, Ribonucleic Acid Modifying Enzymes, Antisense Oligonucleotides, Other Therapy Types), By Route of Administration (Injectable, Oral, Other Routes Of Administration), By Application (Cancer, Neurological Disorders, Metabolic Diseases, Infectious Diseases, Other Applications), By End-User (Hospitals, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Epitranscriptomic Therapies Market Overview

• Epitranscriptomic Therapies market size has reached to $1.56 billion in 2025

• Expected to grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%

• Growth Driver: The Rise In Demand For Personalized Medicine Driving The Growth Of The Market Due To Tailored Patient-Specific Treatments Improving Efficacy And Outcomes

• Market Trend: Collaborative Approaches Accelerate Development Of Ribonucleic Acid -Focused Cancer Therapies

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Epitranscriptomic Therapies Market?

Epitranscriptomic therapies refer to medical treatments that target chemical modifications on ribonucleic acid molecules, such as messenger ribonucleic acid and non-coding ribonucleic acids, to regulate gene expression without altering the underlying deoxyribonucleic acid sequence. These therapies are designed to modulate cellular functions and biological processes, offering potential applications in treating cancer, genetic disorders, and other complex diseases.

The main types of epitranscriptomic therapies include small molecule inhibitors, ribonucleic acid modifying enzymes, antisense oligonucleotides, and other therapy types. Small molecule inhibitors refer to chemical compounds designed to target specific RNA-modifying enzymes for therapeutic purposes. These therapies are administered via injectable, oral, and other routes of administration. The applications include cancer, neurological disorders, metabolic diseases, infectious diseases, and other applications, and the end users are hospitals, research institutes, pharmaceutical and biotechnology companies, and other end users.

Epitranscriptomic Therapies Market Report bar graph

What Is The Epitranscriptomic Therapies Market Size and Share 2026?

The epitranscriptomic therapies market size has grown exponentially in recent years. It will grow from $1.56 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to advancements in rna biology research, growing understanding of gene regulation mechanisms, expansion of oncology research programs, availability of advanced sequencing technologies, increase in translational medicine initiatives.

What Is The Epitranscriptomic Therapies Market Growth Forecast?

The epitranscriptomic therapies market size is expected to see exponential growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%. The growth in the forecast period can be attributed to increasing investments in rna-based therapeutics, rising demand for targeted cancer treatments, expansion of personalized medicine approaches, growing clinical trial activity in epitranscriptomics, increasing regulatory engagement for novel rna therapies. Major trends in the forecast period include increasing development of epitranscriptomic drug pipelines, growing use of rna modification profiling tools, expansion of combination epitranscriptomic therapies, rising integration of bioinformatics in therapy design, enhanced focus on precision medicine applications.

Book your 30 minutes free consultation with our research experts

Global Epitranscriptomic Therapies Market Segmentation

1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types

2) By Route of Administration: Injectable; Oral; Other Routes Of Administration

3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications

4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users

Subsegments:

1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors

2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes

3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides

4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies

What Is The Driver Of The Epitranscriptomic Therapies Market?

The increasing demand for personalized medicine is expected to propel the growth of the epitranscriptomic therapies market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, treatments, and interventions to the individual characteristics of each patient, such as their genetic profile, lifestyle, and environment. The increasing demand for personalized medicine is primarily driven by the rising prevalence of chronic and complex diseases, as tailored treatments can more effectively target individual patient needs and improve outcomes. Personalized medicine supports epitranscriptomic therapies by customizing treatments to an individual’s specific RNA modification patterns, enhancing therapeutic effectiveness while reducing the risk of adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the epitranscriptomic therapies industry.

Key Players In The Global Epitranscriptomic Therapies Market

Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

Global Epitranscriptomic Therapies Market Trends and Insights

Major companies in the epitranscriptomic therapies market are focusing on adopting strategic partnerships to develop innovative RNA-modifying cancer therapies. Strategic partnerships are cooperative arrangements where organizations combine resources, knowledge, or strengths to pursue shared objectives that drive faster growth, lower operational risks, and enhance market competitiveness. For instance, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, partnered with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies targeting epitranscriptomic mechanisms. The collaboration focuses on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials of STC-15, a first-in-class METTL3 inhibitor. This partnership aims to identify and validate m6A RNA modification biomarkers that can predict patient responses and optimize therapeutic strategies. The collaboration combines drug development with advanced RNA profiling, marking a major step forward in epitranscriptomic cancer therapies.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Epitranscriptomic Therapies Market?

In June 2025, Synfini Inc., a US-based biotechnology company, partnered with O2nix Bio Inc. to co-develop novel cancer therapeutics targeting FTSJ1, a tRNA-modifying enzyme involved in metastatic cancer cell survival. This partnership aims to advance the development of epitranscriptomic-based therapies by combining O2nix Bio’s expertise in RNA epitranscriptomics and cancer metastasis biology with Synfini’s AI-driven drug discovery platform that integrates computational design, automated synthesis, and testing. O2nix Bio Inc. is a US-based biotechnology company specializing in RNA biology and epitranscriptomic mechanisms driving cancer metastasis.

Regional Insights

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Epitranscriptomic Therapies Market?

The epitranscriptomic therapies market consists of revenues earned by entities by providing services such as research and development services, contract research organization services, clinical trial services, epitranscriptomic profiling services, bioinformatics and data analysis services, regulatory and consulting services and manufacturing, and process development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Epitranscriptomic Therapies Market Report 2026?

The epitranscriptomic therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the epitranscriptomic therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Epitranscriptomic Therapies Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$1.9 billion
Revenue Forecast In 2035	$4.2 billion
Growth Rate	CAGR of 21.6% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Therapy Type, Route of Administration, Application, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Epitranscriptomic Therapies Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Epitranscriptomic Therapies Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Epitranscriptomic Therapies Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Epitranscriptomic Therapies Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Development Of Epitranscriptomic Drug Pipelines

4.2.2 Growing Use Of Rna Modification Profiling Tools

4.2.3 Expansion Of Combination Epitranscriptomic Therapies

4.2.4 Rising Integration Of Bioinformatics In Therapy Design

4.2.5 Enhanced Focus On Precision Medicine Applications

5. Epitranscriptomic Therapies Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Research Institutes

5.3 Pharmaceutical Companies

5.4 Biotechnology Companies

5.5 Contract Research Organizations

6. Epitranscriptomic Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Epitranscriptomic Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Epitranscriptomic Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Epitranscriptomic Therapies Market Size, Comparisons And Growth Rate Analysis

7.3. Global Epitranscriptomic Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Epitranscriptomic Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Epitranscriptomic Therapies Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Epitranscriptomic Therapies Market Segmentation

9.1. Global Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Small Molecule Inhibitors, Ribonucleic Acid Modifying Enzymes, Antisense Oligonucleotides, Other Therapy Types

9.2. Global Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injectable, Oral, Other Routes Of Administration

9.3. Global Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cancer, Neurological Disorders, Metabolic Diseases, Infectious Diseases, Other Applications

9.4. Global Epitranscriptomic Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

9.5. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Methyltransferase Inhibitors, Demethylase Inhibitors, Reader Protein Inhibitors, Writer Enzyme Inhibitors, Eraser Enzyme Inhibitors

9.6. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Ribonucleic Acid Modifying Enzymes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Methyltransferase Enzymes, Demethylase Enzymes, Pseudouridine Synthase Enzymes, Adenosine Deaminase Enzymes, Cytidine Deaminase Enzymes

9.7. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gapmer Oligonucleotides, Splice Modulating Oligonucleotides, Translation Blocking Oligonucleotides, Exon Skipping Oligonucleotides, Gene Expression Silencing Oligonucleotides

9.8. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ribonucleic Acid Interference Based Therapies, Messenger Ribonucleic Acid Editing Therapies, Epitranscriptomic Vaccine Platforms, Gene Regulation Modulation Therapies, Combination Epitranscriptomic Therapies

10. Epitranscriptomic Therapies Market Regional And Country Analysis

10.1. Global Epitranscriptomic Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Epitranscriptomic Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Epitranscriptomic Therapies Market

11.1. Asia-Pacific Epitranscriptomic Therapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Epitranscriptomic Therapies Market

12.1. China Epitranscriptomic Therapies Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Epitranscriptomic Therapies Market

13.1. India Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Epitranscriptomic Therapies Market

14.1. Japan Epitranscriptomic Therapies Market Overview

14.2. Japan Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Epitranscriptomic Therapies Market

15.1. Australia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Epitranscriptomic Therapies Market

16.1. Indonesia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Epitranscriptomic Therapies Market

17.1. South Korea Epitranscriptomic Therapies Market Overview

17.2. South Korea Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Epitranscriptomic Therapies Market

18.1. Taiwan Epitranscriptomic Therapies Market Overview

18.2. Taiwan Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Epitranscriptomic Therapies Market

19.1. South East Asia Epitranscriptomic Therapies Market Overview

19.2. South East Asia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Epitranscriptomic Therapies Market

20.1. Western Europe Epitranscriptomic Therapies Market Overview

20.2. Western Europe Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Epitranscriptomic Therapies Market

21.1. UK Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Epitranscriptomic Therapies Market

22.1. Germany Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Epitranscriptomic Therapies Market

23.1. France Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Epitranscriptomic Therapies Market

24.1. Italy Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Epitranscriptomic Therapies Market

25.1. Spain Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Epitranscriptomic Therapies Market

26.1. Eastern Europe Epitranscriptomic Therapies Market Overview

26.2. Eastern Europe Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Epitranscriptomic Therapies Market

27.1. Russia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Epitranscriptomic Therapies Market

28.1. North America Epitranscriptomic Therapies Market Overview

28.2. North America Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Epitranscriptomic Therapies Market

29.1. USA Epitranscriptomic Therapies Market Overview

29.2. USA Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Epitranscriptomic Therapies Market

30.1. Canada Epitranscriptomic Therapies Market Overview

30.2. Canada Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Epitranscriptomic Therapies Market

31.1. South America Epitranscriptomic Therapies Market Overview

31.2. South America Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Epitranscriptomic Therapies Market

32.1. Brazil Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Epitranscriptomic Therapies Market

33.1. Middle East Epitranscriptomic Therapies Market Overview

33.2. Middle East Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Epitranscriptomic Therapies Market

34.1. Africa Epitranscriptomic Therapies Market Overview

34.2. Africa Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Epitranscriptomic Therapies Market Regulatory and Investment Landscape

36. Epitranscriptomic Therapies Market Competitive Landscape And Company Profiles

36.1. Epitranscriptomic Therapies Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Epitranscriptomic Therapies Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Epitranscriptomic Therapies Market Company Profiles

36.3.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

36.3.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Epitranscriptomic Therapies Market Other Major And Innovative Companies

Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., O2nix Bio

38. Global Epitranscriptomic Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Epitranscriptomic Therapies Market

41. Epitranscriptomic Therapies Market High Potential Countries, Segments and Strategies

41.1 Epitranscriptomic Therapies Market In 2030 - Countries Offering Most New Opportunities

41.2 Epitranscriptomic Therapies Market In 2030 - Segments Offering Most New Opportunities

41.3 Epitranscriptomic Therapies Market In 2030 - Growth Strategies

41.3.1 Market Trend Based Strategies

41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations

42.2. Currencies

42.3. Historic And Forecast Inflation Rates

42.4. Research Inquiries

42.5. The Business Research Company

42.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Epitranscriptomic Therapies Market, Overview Of Key Products - Product Examples

Table 2: Global Epitranscriptomic Therapies Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Epitranscriptomic Therapies Market, Supply Chain Analysis

Table 4: Global Epitranscriptomic Therapies Market, Major Raw Material Providers

Table 5: Global Epitranscriptomic Therapies Market, Major Resource Providers

Table 6: Global Epitranscriptomic Therapies Market, Major Manufacturers (Suppliers)

Table 7: Global Epitranscriptomic Therapies Market, Major Distributors And Channel Partners

Table 8: Global Epitranscriptomic Therapies Market, Key Technologies & Future Trends

Table 9: Global Epitranscriptomic Therapies Market, Major Trends

Table 10: Global Epitranscriptomic Therapies Market, Major End Users

Table 11: Global Epitranscriptomic Therapies Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Epitranscriptomic Therapies Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Epitranscriptomic Therapies Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Epitranscriptomic Therapies Market - TAM, US$ Billion, 2025

Table 15: Global Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Epitranscriptomic Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Ribonucleic Acid Modifying Enzymes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Epitranscriptomic Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Epitranscriptomic Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Global Epitranscriptomic Therapies Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 98: Global Epitranscriptomic Therapies Market - Company Scoring Matrix

Table 99: Upcoming Startups

Table 100: AstraZeneca PLC Financial Performance

Table 101: GSK plc Financial Performance

Table 102: Moderna Inc. Financial Performance

Table 103: Alnylam Pharmaceuticals Inc. Financial Performance

Table 104: Ionis Pharmaceuticals Inc. Financial Performance

Table 105: Global Epitranscriptomic Therapies Market, Competitive Benchmarking (In USD Billions)

Table 106: Global Epitranscriptomic Therapies Market, Competitive Dashboard

Table 107: Global Epitranscriptomic Therapies Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Therapy Type, 2025 – 2030

Table 109: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

Table 110: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030

List Of Figures

Figure 1: Global Epitranscriptomic Therapies Market, Overview Of Key Products - Product Examples

Figure 2: Global Epitranscriptomic Therapies Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Epitranscriptomic Therapies Market, Supply Chain Analysis

Figure 4: Global Epitranscriptomic Therapies Market, Major Raw Material Providers

Figure 5: Global Epitranscriptomic Therapies Market, Major Resource Providers

Figure 6: Global Epitranscriptomic Therapies Market, Major Manufacturers (Suppliers)

Figure 7: Global Epitranscriptomic Therapies Market, Major Distributors And Channel Partners

Figure 8: Global Epitranscriptomic Therapies Market, Key Technologies & Future Trends

Figure 9: Global Epitranscriptomic Therapies Market, Major Trends

Figure 10: Global Epitranscriptomic Therapies Market, Major End Users

Figure 11: Global Epitranscriptomic Therapies Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Epitranscriptomic Therapies Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Epitranscriptomic Therapies Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Epitranscriptomic Therapies Market - TAM, US$ Billion, 2025

Figure 15: Global Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Epitranscriptomic Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Ribonucleic Acid Modifying Enzymes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Epitranscriptomic Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Epitranscriptomic Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Global Epitranscriptomic Therapies Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 98: Global Epitranscriptomic Therapies Market - Company Scoring Matrix

Figure 99: Upcoming Startups

Figure 100: AstraZeneca PLC Financial Performance

Figure 101: GSK plc Financial Performance

Figure 102: Moderna Inc. Financial Performance

Figure 103: Alnylam Pharmaceuticals Inc. Financial Performance

Figure 104: Ionis Pharmaceuticals Inc. Financial Performance

Figure 105: Global Epitranscriptomic Therapies Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global Epitranscriptomic Therapies Market, Competitive Dashboard

Figure 107: Global Epitranscriptomic Therapies Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Therapy Type, 2025 – 2030

Figure 109: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

Figure 110: Global, Epitranscriptomic Therapies Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

eCOA, eSource And Clinical Trials Market Report 2026 - Global Outlook – By Solution Type (eCOA (Electronic Clinical Outcome Assessment), eSource, Clinical Trial Solutions, Electronic Data Capture (EDC)), By Deployment (L...

Epilepsy Drugs Market Report 2026 - Global Outlook – By Seizure Type (Focal Seizures, Generalized Seizures), By Generation Type (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-...

Gene Therapy Market Report 2026 - Global Outlook – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis,...

Pharmacogenomics Market Report 2026 - Global Outlook – By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies), By Application (Neurol...

Cell And Gene Therapy Clinical Trial Services Market Report 2026 - Global Outlook – By Service (Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Bio...

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026 - Global Outlook – By Service Type (Contract Research Organizations (CROs), Contract Development And Manufacturing Organizations (CDMOs)), By Indication...

Anti-Neoplastic Agents Market Report 2026 - Global Outlook – By Type (Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous), By Disease Type (Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, ...

Frequently Asked Questions

How big is the Epitranscriptomic Therapies Market?

The Epitranscriptomic Therapies market was valued at $1.56 billion in 2025, increased to $1.9 billion in 2026, and is projected to reach $4.2 billion by 2030.

What is the Epitranscriptomic Therapies market growth?

The global Epitranscriptomic Therapies market is expected to grow at a CAGR of 21.9% from 2026 to 2035 to reach $4.2 billion by 2035.

Who are the key players in Epitranscriptomic Therapies market?

Some Key Players in the Epitranscriptomic Therapies market Include, AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio. .

What is the anticipated growth trend for the Epitranscriptomic Therapies market?

Major trend in this market includes: Collaborative Approaches Accelerate Development Of Ribonucleic Acid -Focused Cancer Therapies. For further insights on this market. request a sample here

Which region has the most growth potential in the Epitranscriptomic Therapies market?

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.